The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sci Rep
Hoofdauteurs: Xin, Shuang, Zhao, Yuanyuan, Wang, Xueding, Huang, Yan, Zhang, Jing, Guo, Ying, Li, Jiali, Li, Hongliang, Ma, Yuxiang, Chen, Lingyan, Hu, Zhihuang, Huang, Min, Zhang, Li
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/
https://ncbi.nlm.nih.gov/pubmed/26228025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items